MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...

Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...

The concept of skipping axillary lymph node dissection (ALND) in some patients with breast cancer was supported by a European noninferiority trial. Among patients with early-stage, node-negative ...

Omitting axillary lymph node dissection does not increase the risk for recurrence or compromise 5-year overall survival outcomes in patients with early-stage, node-negative breast cancer with sentinel ...

The management of axillary lymph nodes in breast cancer is continually evolving. Recent data now support omitting axillary lymph node dissection (ALND) in most patients with metastases in up to two ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Trends and outcomes in patients receiving neoadjuvant chemotherapy for breast cancer in Ontario: A population-based study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

Please provide your email address to receive an email when new articles are posted on . Patients with early invasive breast cancer who did not receive axillary surgery had noninferior outcomes as ...

We used FDG-PET/CT scans to assess the extent of cancer spread to the lymph nodes," said Dr Van Hemert. "We marked the largest axillary lymph node with a radioactive iodine seed. After this, patients ...